European Journal of Medicinal Chemistry最新文献

筛选
英文 中文
Discovery of a highly potent DDR1/2 inhibitor with good kinase selectivity and strong anti-inflammatory efficacy in a mouse model of acute kidney injury 发现一种高效的DDR1/2抑制剂,在小鼠急性肾损伤模型中具有良好的激酶选择性和较强的抗炎作用
IF 6.7 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-10-29 DOI: 10.1016/j.ejmech.2026.119470
Michael Härter, Michael Koch, Jan Dreher, Anja Giese, Fabian Göricke, Klemens Lustig, Jürgen Klar, Ambra Pozzi, Corina M. Borza
{"title":"Discovery of a highly potent DDR1/2 inhibitor with good kinase selectivity and strong anti-inflammatory efficacy in a mouse model of acute kidney injury","authors":"Michael Härter, Michael Koch, Jan Dreher, Anja Giese, Fabian Göricke, Klemens Lustig, Jürgen Klar, Ambra Pozzi, Corina M. Borza","doi":"10.1016/j.ejmech.2026.119470","DOIUrl":"https://doi.org/10.1016/j.ejmech.2026.119470","url":null,"abstract":"Discoidin Domain Receptors 1 and 2 (DDR1/2) are receptor tyrosine kinases activated by collagen. Their upregulation and activation are observed in various human diseases, including kidney disease, with most evidence existing for DDR1. Several small-molecule DDR1 inhibitors have shown efficacy in diverse animal models of kidney injury and disease; yet none of them have entered clinical trials. Here, we report on the discovery of a new chemical series of small-molecule DDR inhibitors, based on a dihydropyridopyrimidinyl-benzamide scaffold, and its subsequent hit-to-lead optimization. The chemical series was identified from an in-house screening library by independent virtual and ultra-high throughput screening. The initial screening hit was optimized for potency, kinase selectivity and pharmacokinetic properties, and gave rise to a lead compound suitable for pharmacological <ce:italic>in vivo</ce:italic> studies. The lead compound BAY-852 inhibited collagen-induced receptor activation in kidney cells with IC<ce:inf loc=\"post\">50</ce:inf> values below 1 nM, consistent with the potencies in biochemical assays. In a model of ischemia reperfusion-induced acute kidney injury (AKI), BAY-852 – when administered <ce:italic>via</ce:italic> oral gavage at 2 mg/kg – blocked injury-induced DDR1 phosphorylation, reduced the levels of KIM-1, a marker of tubular injury, and reduced inflammatory cell infiltration. The low effective <ce:italic>in vivo</ce:italic> dose confirms the high potency and the excellent pharmacokinetic properties of BAY-852. Based on these results, the lead compound shows promise and warrants further exploration in animal models of human diseases where DDR1 is upregulated and activated.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"22 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149292304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, Synthesis and SAR Studies of N’-(Heteroarylsalicylidene)- and N’-(Fused-heterobicyclosalicylidene)-N-arenecarbohydrazides as Next-Generation Broad-Spectrum Antifungal Agents 新一代广谱抗真菌剂N′-(杂芳基水杨基)-和N′-(融合杂双环水杨基)-N-壬基糖酰肼的设计、合成及SAR研究
IF 6.7 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-10-24 DOI: 10.1016/j.ejmech.2026.119426
Ashna Garg, Nathalia Fidelis Vieira de Sa, Ananya Shibana Thennarasu, Kathryn Takemura, Gabriel S. Matos, Jacob Acosta, Neelu Singh, Caroline Correa De Almeida, Nivea Pereira De Sa, Maurizio Del Poeta, Iwao Ojima
{"title":"Design, Synthesis and SAR Studies of N’-(Heteroarylsalicylidene)- and N’-(Fused-heterobicyclosalicylidene)-N-arenecarbohydrazides as Next-Generation Broad-Spectrum Antifungal Agents","authors":"Ashna Garg, Nathalia Fidelis Vieira de Sa, Ananya Shibana Thennarasu, Kathryn Takemura, Gabriel S. Matos, Jacob Acosta, Neelu Singh, Caroline Correa De Almeida, Nivea Pereira De Sa, Maurizio Del Poeta, Iwao Ojima","doi":"10.1016/j.ejmech.2026.119426","DOIUrl":"https://doi.org/10.1016/j.ejmech.2026.119426","url":null,"abstract":"The design, synthesis, biological evaluations and SAR study of <ce:italic>N’</ce:italic>-heteroarylsalicylidene- and <ce:italic>N′</ce:italic>-(fused-heterobicyclosalicylidene)-<ce:italic>N</ce:italic>-arenecarbohydrazides, as the next-generation broad-spectrum antifungal agents effective against fungal pathogens in WHO’s Fungal Priority Pathogen List (FPPL), are reported. A library of 58 compounds thus synthesized were examined for their potency against <ce:italic>C. neoformans, C. albicans</ce:italic> and <ce:italic>A. fumigatus</ce:italic> to select highly potent broad-spectrum lead compounds. Against <ce:italic>C. neoformans</ce:italic>, 52 out of 58 compounds show high potency and 7 compounds, bearing furan and thiazole on the ring B, exhibited extremely high potency (MIC<ce:inf loc=\"post\">80</ce:inf> 0.001∼0.007 μg/mL). A good number of compounds showed high potency against <ce:italic>C. albicans</ce:italic> (MIC<ce:inf loc=\"post\">80</ce:inf><ce:italic>≤</ce:italic> 0.5 μg/mL). In contrast, only 10 out of 58 compounds showed good activity against <ce:italic>A. fumigatus</ce:italic> (MIC<ce:inf loc=\"post\">80</ce:inf> &lt;1 μg/mL).","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"85 1 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149292310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “ Engineering β-amino acid antimicrobial peptides with enhanced stability and potential efficacy against gram-negative bacterial infections” [Eur. J. Med. Chem. 310 (2026) 118802] “工程β-氨基酸抗菌肽增强稳定性和抗革兰氏阴性细菌感染的潜在功效”的勘误表[欧洲]。医学化学。310 (2026)118802]
IF 6.7 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-10-22 DOI: 10.1016/j.ejmech.2026.119444
Jingyi Zhu, Luyang Gao, Wenjing Xue, Jing Zou, Jiahui Wang, Yashi Wang, Yun Zhang, Sanhu Gou, Hui Liu, Chao Zhong, Jingman Ni
{"title":"Corrigendum to “ Engineering β-amino acid antimicrobial peptides with enhanced stability and potential efficacy against gram-negative bacterial infections” [Eur. J. Med. Chem. 310 (2026) 118802]","authors":"Jingyi Zhu, Luyang Gao, Wenjing Xue, Jing Zou, Jiahui Wang, Yashi Wang, Yun Zhang, Sanhu Gou, Hui Liu, Chao Zhong, Jingman Ni","doi":"10.1016/j.ejmech.2026.119444","DOIUrl":"https://doi.org/10.1016/j.ejmech.2026.119444","url":null,"abstract":"","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"21 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149233038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "AVP-GPT2: Prompt-conditioned fine-tuning of a GPT-2 protein language model for antiviral peptide identification" [Eur. J. Med. Chem. 320 (2026) 119352]. “avp - GPT-2:用于抗病毒肽鉴定的GPT-2蛋白语言模型的即时条件微调”的更正[欧洲]。中华医学杂志,2002(5):391 - 391。
IF 6.7 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-10-09 DOI: 10.1016/j.ejmech.2026.119409
Maryam, Hamza Zahid, Kil To Chong, Hilal Tayara
{"title":"Corrigendum to \"AVP-GPT2: Prompt-conditioned fine-tuning of a GPT-2 protein language model for antiviral peptide identification\" [Eur. J. Med. Chem. 320 (2026) 119352].","authors":"Maryam, Hamza Zahid, Kil To Chong, Hilal Tayara","doi":"10.1016/j.ejmech.2026.119409","DOIUrl":"10.1016/j.ejmech.2026.119409","url":null,"abstract":"","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":" ","pages":"119409"},"PeriodicalIF":6.7,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A hierarchical targeting one-for-all small-molecule enabling multimodal tumor therapy via energy blockade and heat-tolerance suppression 通过能量阻断和耐热性抑制,分层靶向“一刀切”小分子实现多模式肿瘤治疗
IF 6.7 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-09-01 DOI: 10.1016/j.ejmech.2026.119299
Zhizhe Li,Haonan Zheng,Yingying Ma,Tingting Li,Shuang Ma,Mi Li,Haiyan Xu,Shide Zheng,Hongqing Guo,Xinyu Wang,Weige Zhang,Qi Guan
{"title":"A hierarchical targeting one-for-all small-molecule enabling multimodal tumor therapy via energy blockade and heat-tolerance suppression","authors":"Zhizhe Li,Haonan Zheng,Yingying Ma,Tingting Li,Shuang Ma,Mi Li,Haiyan Xu,Shide Zheng,Hongqing Guo,Xinyu Wang,Weige Zhang,Qi Guan","doi":"10.1016/j.ejmech.2026.119299","DOIUrl":"https://doi.org/10.1016/j.ejmech.2026.119299","url":null,"abstract":"","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"74 1","pages":"119299"},"PeriodicalIF":6.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148895657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CADD-Based Discovery of Novel Heterocyclic Pyrimidine-Based CDK4/6 Inhibitors: Design, Synthesis, and Anti-Breast Cancer Activity Studies 基于cadd的新型杂环嘧啶类CDK4/6抑制剂的发现:设计、合成和抗乳腺癌活性研究
IF 5.9 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-05-15 DOI: 10.1016/j.ejmech.2026.118932
Xinya Lv , Xiaoling Huang , Lulu Tian , Shidi Xu , Yujie Zhan , Hanrui Hou , Dajun Zhang , Linxiao Wang , Shan Xu
{"title":"CADD-Based Discovery of Novel Heterocyclic Pyrimidine-Based CDK4/6 Inhibitors: Design, Synthesis, and Anti-Breast Cancer Activity Studies","authors":"Xinya Lv ,&nbsp;Xiaoling Huang ,&nbsp;Lulu Tian ,&nbsp;Shidi Xu ,&nbsp;Yujie Zhan ,&nbsp;Hanrui Hou ,&nbsp;Dajun Zhang ,&nbsp;Linxiao Wang ,&nbsp;Shan Xu","doi":"10.1016/j.ejmech.2026.118932","DOIUrl":"10.1016/j.ejmech.2026.118932","url":null,"abstract":"&lt;div&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Forty novel heterocyclic pyrimidine compounds were designed, screened, and synthesized using a CADD strategy as highly potent CDK4/6 inhibitors.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;The lead compound 3c exhibits potent CDK4/6 kinase inhibitory activity, with an IC50 in the nM range.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Compound 3c induces G1 phase arrest and apoptosis in MCF-7 cancer cells by inhibiting the phosphorylation of the Rb protein.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;The lead compound demonstrates good in vivo tumor-suppressing activity and acceptable biosafety, making it worthy of further development.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Cyclin-dependent kinase 4/6 (CDK4/6) plays a pivotal role in cell cycle regulation, and its abnormal activation is closely associated with the initiation and progression of breast cancer.1 However, the limited number of clinically available CDK4/6 inhibitors restricts treatment options. This study focuses on the design, synthesis, and antitumor activity investigation of novel CDK4/6 inhibitors.Employing computer-aided drug design (CADD) strategies and utilizing drug-like and bioisostere principles, we innovatively introduced pyridine-2-aminopyrimidine, thieno[3,2-d]pyrimidine, and pyrazolo[1,5-a]pyrimidine as core skeletal structures to design and screen 250 compound molecules. Based on computational results, including molecular docking and MM/GBSA binding free energy, 40 potential novel CDK4/6 inhibitors were selected for synthesis.Cellular assays validated that compound 3c exhibited the strongest inhibitory activity against CDK4/6 in breast cancer cell lines, with IC&lt;sub&gt;50&lt;/sub&gt; values of 0.11 ± 0.01 μM (MCF-7), 0.21 ± 0.01 μM (4T1), and 0.12 ± 0.01 μM (MDA-MB-231). And compound &lt;strong&gt;3c&lt;/strong&gt; demonstrated favorable CDK4/6 inhibition rates and showed a certain degree of selectivity among 23 kinases. In vitro mechanistic studies revealed that &lt;strong&gt;3c&lt;/strong&gt; consistently inhibited cell colony formation and migration. Furthermore, &lt;strong&gt;3c&lt;/strong&gt; effectively arrested the MCF-7 cell cycle at the G1 phase and induced apoptosis. In the MCF-7 xenograft model, compound &lt;strong&gt;3c&lt;/strong&gt; achieved a tumor inhibition rate of 45.20%, highlighting its significant potential as a therapeutic CDK4/6 inhibitor.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Cyclin-dependent kinase 4/6 (CDK4/6) plays a pivotal role in cell cycle regulation, and its abnormal activation is closely associated with the initiation and progression of breast cancer.1 However, the limited number of clinically available CDK4/6 inhibitors restricts treatment options. This study focuses on the design, synthesis, and antitumor activity investigation of novel CDK4/6 inhibitors.Employing computer-aided drug design (CADD) strategies and utilizing drug-like and bioisostere principles, we innovatively introduced pyridine-2-aminopyrimidine, thieno[3,2-d]pyrimidine, and pyrazolo[1,5-a]pyrimidine as co","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"315 ","pages":"Article 118932"},"PeriodicalIF":5.9,"publicationDate":"2026-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147999287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of novel ENPP1 inhibitors with benzotriazole core for cancer immunotherapy 以苯并三唑为核心的新型肿瘤免疫治疗ENPP1抑制剂的发现
IF 5.9 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-04-05 Epub Date: 2026-02-10 DOI: 10.1016/j.ejmech.2026.118666
Junghwan Choi , Sunwoo Lee , Yong-Yea Park , Jihun Kim , Haein Kim , Kyeongwon Moon , Sunyoung Park , Eun Kyung Yoo , Chang Won Min , Hyouk Woo Lee , Hyun-Ju Park , Pargat Singh , Sungjoon Kim , Chan Sun Park , In Su Kim
{"title":"Discovery of novel ENPP1 inhibitors with benzotriazole core for cancer immunotherapy","authors":"Junghwan Choi ,&nbsp;Sunwoo Lee ,&nbsp;Yong-Yea Park ,&nbsp;Jihun Kim ,&nbsp;Haein Kim ,&nbsp;Kyeongwon Moon ,&nbsp;Sunyoung Park ,&nbsp;Eun Kyung Yoo ,&nbsp;Chang Won Min ,&nbsp;Hyouk Woo Lee ,&nbsp;Hyun-Ju Park ,&nbsp;Pargat Singh ,&nbsp;Sungjoon Kim ,&nbsp;Chan Sun Park ,&nbsp;In Su Kim","doi":"10.1016/j.ejmech.2026.118666","DOIUrl":"10.1016/j.ejmech.2026.118666","url":null,"abstract":"<div><div>The cGAS-STING signaling pathway is an essential mechanism in the recruitment and activation of innate and adaptive immune cells to exert an antitumor response in cancer immunotherapy. cGAMP is a crucial immunotransmitter, which is potentially degraded by ENPP1, resulting in the deactivation of STING-mediated antitumor immune responses. We herein describe the design, synthesis, and biological evaluation of novel ENPP1 inhibitors containing a benzotriazole core and a sulfonimidamide Zn binder. Notably, compound <strong>44a</strong> demonstrated potent and selective ENPP1 inhibition with an IC<sub>50</sub> value of 13.1 nM and effectively activated the STING pathway in HCT116-Dual™ cells. Additionally, compound <strong>44a</strong> exhibited a notable release of cytokines in THP-1 cell lines, thereby enhancing the innate immune response. The oral administration of compound <strong>44a</strong> displayed remarkable antitumor efficacy in the MC38 syngeneic mouse model without notable toxicity. Therefore, compound <strong>44a</strong> can be considered a promising candidate as a selective and orally bioavailable ENPP1 inhibitor.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118666"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146153257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xanthine oxidase inhibitors for gout: Applications and novel drug development 痛风的黄嘌呤氧化酶抑制剂:应用和新药开发
IF 5.9 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-04-05 Epub Date: 2026-02-06 DOI: 10.1016/j.ejmech.2026.118619
Weiping Lyu , Haoming Qin , Xiaonan Zhou , Yihan Zhang , Dehua Lu , Yongxiang Shao , Yanming Chen , Mingxiu Liang , Qi Li , Xiaowei Chi , Liangren Zhang , Cheng Shi , Zhenming Liu
{"title":"Xanthine oxidase inhibitors for gout: Applications and novel drug development","authors":"Weiping Lyu ,&nbsp;Haoming Qin ,&nbsp;Xiaonan Zhou ,&nbsp;Yihan Zhang ,&nbsp;Dehua Lu ,&nbsp;Yongxiang Shao ,&nbsp;Yanming Chen ,&nbsp;Mingxiu Liang ,&nbsp;Qi Li ,&nbsp;Xiaowei Chi ,&nbsp;Liangren Zhang ,&nbsp;Cheng Shi ,&nbsp;Zhenming Liu","doi":"10.1016/j.ejmech.2026.118619","DOIUrl":"10.1016/j.ejmech.2026.118619","url":null,"abstract":"<div><div>Hyperuricemia is a well-established direct trigger of gouty arthritis. Xanthine oxidase (XO), the rate-limiting enzyme in uric acid production, represents a core therapeutic target for gout. Although XO inhibitors like allopurinol and febuxostat are widely-used clinically, their limitations, including severe hypersensitivity and cardiovascular risks, necessitate the continuous pursuit of safer and more efficient agents. This review provides a systematic and critical assessment of recent advances in XO inhibitor research, proposing for the first time a unified classification framework based on the evolution of drug design strategies. We comprehensively cover diverse chemical entities, from structure-based, rationally designed compounds to natural products and their corresponding analogs, with a particular emphasis on cutting-edge strategies designed to overcome existing drawbacks. These include dual-target inhibitors (e.g., targeting XO/URAT1 or XO/NLRP3) and drug repurposing. By delving into the structure-activity relationships within each inhibitor class, we identify crucial pharmacophores and optimization principles. Finally, the review offers a forward-looking perspective, critically discussing current research challenges and outlining future directions, such as leveraging artificial intelligence and advanced computational simulations for lead optimization. This work is intended to serve as a clear theoretical blueprint and a practical source of inspiration for medicinal chemists designing the next generation of highly effective and low-toxicity anti-gout therapeutics.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118619"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146135339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural optimization of AR and AR-V7 degraders incorporating silicon-based hydrophobic tags for treatment of castration-resistant prostate cancer 含有硅基疏水标签的AR和AR- v7降解剂治疗去势抵抗性前列腺癌的结构优化
IF 5.9 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-04-05 Epub Date: 2026-01-31 DOI: 10.1016/j.ejmech.2026.118617
Lei Xu , Mengmeng Wang , Yanshuo Cheng , Hanhan Kuang , Yijing Zhu , Ning Liu , Qianqian Wang , Shicong Li , Jiefu Wang , Junfeng Wang , Ziqi Huang , Ranlu Liu , Shuangwei Liu , Kun Zhang , Guang Yang
{"title":"Structural optimization of AR and AR-V7 degraders incorporating silicon-based hydrophobic tags for treatment of castration-resistant prostate cancer","authors":"Lei Xu ,&nbsp;Mengmeng Wang ,&nbsp;Yanshuo Cheng ,&nbsp;Hanhan Kuang ,&nbsp;Yijing Zhu ,&nbsp;Ning Liu ,&nbsp;Qianqian Wang ,&nbsp;Shicong Li ,&nbsp;Jiefu Wang ,&nbsp;Junfeng Wang ,&nbsp;Ziqi Huang ,&nbsp;Ranlu Liu ,&nbsp;Shuangwei Liu ,&nbsp;Kun Zhang ,&nbsp;Guang Yang","doi":"10.1016/j.ejmech.2026.118617","DOIUrl":"10.1016/j.ejmech.2026.118617","url":null,"abstract":"<div><div>Androgen receptor splice variant 7 (AR-V7) plays a crucial role in the malignant progression of castration-resistant prostate cancer (CRPC). Current research has demonstrated that the development of novel AR-V7 degraders holds broad prospects and is expected to serve as a clinical therapeutic regimen for this disease. In the present work, we utilized structural analogs of enzalutamide to conjugate a silicon-containing hydrophobic tag (SiHyT) moiety via Click chemistry, achieving the selective degradation of the androgen receptor (AR) and AR-V7. Mechanistic studies revealed that the degrader disrupted the interactions between AR/AR-V7 and HSP90. This disruption further prompted the E3 ubiquitin ligase helicase-like transcription factor (HLTF) to recognize AR and AR-V7, followed by their ubiquitination and degradation in CRPC cell lines. Additionally, the active compound exhibited favorable pharmacokinetic properties and metabolic profiles. In both <em>in vitro</em> and <em>in vivo</em> experiments, this degrader displayed more potent activity than enzalutamide in inhibiting the proliferation and migration of CRPC cells. This study expands the application scope of the silicon-containing hydrophobic tag (SiHyT) strategy and provides an alternative design concept for the development of drugs targeting the degradation of AR/AR-V7 in the treatment of CRPC.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118617"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146095637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisation 新的抗结核Pretomanid类似物作为聚合物胶束的有效载荷:利用斑马鱼试验加速先导优化
IF 5.9 2区 医学
European Journal of Medicinal Chemistry Pub Date : 2026-04-05 Epub Date: 2026-01-30 DOI: 10.1016/j.ejmech.2026.118622
Andrew M. Thompson , Nils-Jørgen K. Dal , Francesca Boldrin , Noelia Alonso-Rodriguez , Gabriela Schäfer , Kerstin Johann , Martin Speth , Laura Cioetto-Mazzabò , Adrián Pál , Jana Korduláková , Matthias Barz , Federico Fenaroli , William A. Denny , Gareth Griffiths
{"title":"New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisation","authors":"Andrew M. Thompson ,&nbsp;Nils-Jørgen K. Dal ,&nbsp;Francesca Boldrin ,&nbsp;Noelia Alonso-Rodriguez ,&nbsp;Gabriela Schäfer ,&nbsp;Kerstin Johann ,&nbsp;Martin Speth ,&nbsp;Laura Cioetto-Mazzabò ,&nbsp;Adrián Pál ,&nbsp;Jana Korduláková ,&nbsp;Matthias Barz ,&nbsp;Federico Fenaroli ,&nbsp;William A. Denny ,&nbsp;Gareth Griffiths","doi":"10.1016/j.ejmech.2026.118622","DOIUrl":"10.1016/j.ejmech.2026.118622","url":null,"abstract":"<div><div>Third-generation derivatives of the tuberculosis drug pretomanid featuring acetylene-bridged aryl-heteroaryl or heterotriaryl side chains were designed as novel agents for nanoparticle-based delivery, seeking better efficacy and safety. While all nitro compounds retained excellent activity against <em>Mycobacterium tuberculosis</em>, several examples in the latter class excelled as having potency superior to the original lead (<strong>7</strong>) but equivalent to or reduced lipophilicity, implying enhanced lipophilic efficiency. Initial studies suggested a similar mode of action against the related fish pathogen, <em>M. marinum</em>; therefore, fourteen candidates were further assessed as micellar formulations in <em>M. marinum-</em>infected zebrafish embryo assays. Overall, the best new analogue was <strong>14</strong> (the 6-amino-linked congener of <strong>7</strong>), which was non-toxic and displayed efficacy comparable to <strong>7</strong> in both the blood and neural tube <em>M. marinum</em> infection models. Lead <strong>14</strong> also exhibited high microsomal stability, moderate cell permeability in an MDR1-MDCKII screen, and an enhanced pharmacokinetic profile in mice, with 93 % oral bioavailability.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"307 ","pages":"Article 118622"},"PeriodicalIF":5.9,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书